Betamox LA, whose active ingredient is amoxicillin, is an antibiotic commonly used across conditions presenting with acute episodes of bacterial infection in livestock and companion animals. Its primary function is to provide an extended-release formulation, which may offer prolonged symptomatic relief and helps with the overall symptom load during periods of heightened discomfort. Amoxicillin may be part of symptomatic management for bacterial infections.

Related veterinary amoxicillin formulations are applied in addressing a variety of infections. These indications generally cover symptoms linked to organ-specific functional stress in the respiratory tract, genitourinary tract (like cystitis), and gastrointestinal tract, as well as symptoms related to inflammatory or irritative states in the skin and soft tissues (such as abscesses and wounds). The long-acting (LA) action assists with maintaining functional stability during phases when symptoms become more noticeable, making it a relevant option for managing infections where short-term symptomatic assistance is needed. The LA formulation **supports patients during episodes of heightened discomfort.

“The long-acting action may assist with maintaining a sense of stability when symptoms are more noticeable.”

Quick Fact: May assist with Symptoms Related to Systemic Imbalance

Regulatory References

1. Amoxi-Tabs prescribing information from the National Library of Medicine

Who Can and Cannot Use Betamox LA?

This medication is officially authorized for use in cattle, sheep, pigs, dogs, and cats.

Contraindicated and Restricted Populations

Contraindicated: Use is strictly prohibited for animals with a known history of hypersensitivity (allergy) to penicillins or cephalosporins.

Species Prohibited: The product must not be administered to rabbits, hamsters, gerbils, or guinea pigs (small herbivores).

Route of Administration: The medication is not suitable for intravenous or intrathecal (into the spinal fluid) administration in any species.

Pregnancy and Lactation Eligibility

The product is generally considered safe and can be administered during pregnancy and lactation in the authorized target species. However, it is contraindicated for use in sheep producing milk for human consumption due to regulatory concerns regarding milk residues.

Interactions with other medicines and products

The regulatory documentation for Amoxicillin, the active ingredient in Betamox LA, specifies several official interaction patterns, primarily categorized by effects on clearance, drug exposure, and pharmacodynamic outcomes.

Effects on Drug Exposure

Co-administration with Probenecid is documented to decrease the renal tubular secretion of Amoxicillin, officially resulting in increased and prolonged plasma concentrations of the antibiotic. This pharmacokinetic effect is a specific consideration in patients with impaired renal function, where decreased renal clearance naturally leads to higher Amoxicillin blood concentrations. Amoxicillin also reduces the renal elimination of Methotrexate, a mechanism that increases the potential for Methotrexate-related side effects.

Pharmacodynamic Effects and Efficacy

Specific pharmacodynamic interactions are noted for agents that alter drug activity or risk. Concomitant use with oral anticoagulants may be associated with an increase in the International Normalized Ratio (INR). Co-administration with Allopurinol increases the officially documented incidence of skin rash. Furthermore, bacteriostatic antibacterials, such as macrolides, sulfonamides, and tetracyclines, may interfere with the bactericidal effects of penicillins. Amoxicillin may also reduce the efficacy of combined oral estrogen/progesterone contraceptives.

Laboratory Test Interference

Amoxicillin high urine concentrations may result in false-positive reactions when testing for glucose using non-enzymatic methods, such as CLINITEST® solution.

How Betamox LA Works

Betamox LA (Amoxicillin) is a beta-lactam antibiotic that acts by interfering with a structural process critical for maintaining bacterial cell integrity. Its mechanism is strictly bactericidal, meaning it directly causes the death of the target organisms.

---

Targeting the Bacterial Cell Wall Synthesis

The primary action of Betamox LA is within the mechanistic domain of cell wall construction. The drug acts as an inhibitor by binding irreversibly to bacterial enzymes called Penicillin-Binding Proteins (PBPs), which are responsible for the final stage of peptidoglycan cross-linking. This targeted inhibition prevents the bacterium from completing its rigid protective wall, resulting in a compromise of structural integrity.

---

Disruption of Peptidoglycan Cross-Linking

This mechanistic cascade involves the specific blockade of the transpeptidation reaction. By neutralizing the PBPs, Betamox LA prevents the necessary molecular bonds from forming within the peptidoglycan layer. The resulting physiological effect is a structural failure that compromises the cell's integrity against the external environment. This leads directly to osmotic lysis (rupture), which results in bacterial cell death (lysis).

How to Use Betamox LA

Betamox LA is a long-acting injectable veterinary medicine containing Amoxicillin at a strength of 150 mg per mL of suspension. Its usage is governed by precise instructions concerning the route, dosage, frequency, and administration technique, ensuring the medicine is delivered correctly for its prolonged action.

---

Administration Route and Dose Calculation

Administration is strictly by parenteral injection. The approved route varies by species: for cattle, sheep, and pigs, the route is restricted to intramuscular (IM) injection. For dogs and cats, either subcutaneous (SC) or intramuscular (IM) injection may be used. The medicine is not approved for intravenous or intrathecal use.

The standard dosage rate is uniform across all approved target species, requiring 15 mg of amoxicillin per kilogram (mg/kg) of bodyweight. This translates to a volume of 1 mL of the suspension for every 10 kg of bodyweight. It is required that the animal's bodyweight is determined accurately for correct dosing.

---

Frequency and Procedural Constraints

The formulation is designed for a single initial injection to provide sustained therapeutic levels for 48 hours. If clinical signs of the bacterial infection persist after that period, the dose may be repeated once after 48 hours, limiting the entire course of therapy to a maximum of two administrations.

Prior to drawing the dose, the vial must be shaken well to fully suspend the active ingredient. Specific constraints on the volume administered per site must be observed; for instance, volumes exceeding 15 mL in cattle or 4 mL in sheep and pigs must be divided and administered into multiple, separate injection sites.

Research Evidence / Overview of Studies for Betamox LA

The body of research for Betamox LA (Amoxicillin LA Injection) focuses on Clinical Field Trials and specialized Pharmacokinetic (PK) studies to investigate its use in infections caused by susceptible bacteria in livestock and companion animals. The evidence cited in regulatory documentation helps show what has been observed so far in specific animal populations, but study results reflect the specific conditions under which they were conducted.

---

Evidence for Use in Treating Acute Systemic Infections

This section summarizes the structure of Clinical Field Trials and specialized PK studies that assessed the long-acting formulation across common acute bacterial infections, including those affecting the alimentary, respiratory, urogenital, and skin/soft tissues. Clinical Field Trials was studied for the control of conditions associated with acute or disruptive episodes. The research monitored outcomes related to physical discomfort and systemic or functional imbalance. Findings describe patterns related to how symptoms evolved and the monitored reduction of susceptible bacteria. The evidence generally contributes to the broader evidence landscape for understanding these acute bacterial events in authorized species.

---

Research on the Long-Acting (LA) Formulation and Therapeutic Duration

Specialized PK studies examined how the long-acting suspension maintains antibiotic concentration in the body. The goal of this research was to confirm that the formulation can maintain antibiotic concentrations over an extended period (up to 48 hours) following a single administration. The findings describe patterns related to the drug's extended half-life and tissue distribution, providing insight into the formulation's prolonged half-life profile compared to standard forms of Amoxicillin.

---

What Regulatory Research Does Not Fully Address

A primary limitation is that results apply only to the populations studied; the evidence is strictly limited to veterinary contexts and is not transferable to human medicine. Furthermore, research describes that the active ingredient, Amoxicillin, is typically not studied for use against organisms that produce beta-lactamase, due to known resistance mechanisms. Observed response in trials is strictly dependent on the pathogen's susceptibility. Long-term effects are not fully established as follow-up durations were limited to the acute treatment phase, and there is limited information for long-term outcomes following its use.

Key Studies & References

1. Summary of Product Characteristics (SPC): Betamox LA 150 mg/ml Suspension for Injection (Veterinary Medicines Directorate, UK)
2. Amoxicillin - Monograph on Veterinary Use (Food and Agriculture Organization of the United Nations - FAO)

Common questions about Betamox LA (FAQ)

Q: What is Betamox LA used for?

Betamox LA is indicated for the treatment of certain infections caused by susceptible bacteria. The specific indications for its use are detailed in the official product labeling.

Q: How should I store this medication?

The official product label provides specific guidance on storage conditions, including temperature and protection from light or moisture. It is important to review this information to maintain the product's quality.

Q: Can I give Betamox LA to a pregnant or nursing animal?

Information regarding the use of Betamox LA in pregnant or lactating animals is available in the product's safety information. A veterinarian is the best source to determine if the benefits outweigh the potential risks in these specific situations.

Q: What are the possible side effects of Betamox LA?

As with any medication, side effects may occur. The official labeling lists known adverse reactions. If any unusual or severe reactions are observed, immediate consultation with a veterinary professional is recommended.

Betamox LA must be stored carefully to maintain its effectiveness. Keep the product below 25 C and protect it from light and freezing. It is essential to keep the medication out of the sight and reach of children.

After the initial use of the vial (first broaching), the product must be used within 28 days. Any unused portion remaining after this 28-day period should be discarded promptly as the product does not contain an antimicrobial preservative for extended in-use stability.

Disposal of any unused veterinary medicinal product or waste materials derived from its use must be done in accordance with local requirements. Do not dispose of the medication in wastewater or household garbage unless specifically instructed by local waste regulation authorities. Consult a veterinarian or pharmacist regarding appropriate local take-back schemes for proper disposal.